Organon & Co. (NYSE:OGN) Sets New 1-Year High – Here’s What Happened

Organon & Co. (NYSE:OGN) reached a new 52-week high during trading on Tuesday . The company traded as high as $13.76 and last traded at $13.7540, with a volume of 4583387 shares trading hands. The stock had previously closed at $13.75.

Analyst Ratings Changes

OGN has been the subject of a number of research analyst reports. BNP Paribas Exane restated a “neutral” rating and issued a $14.00 target price (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Weiss Ratings cut Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Five investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Trading Up 0.1%

The business’s 50-day simple moving average is $13.57 and its 200-day simple moving average is $11.04. The company has a market cap of $3.62 billion, a PE ratio of 17.88, a P/E/G ratio of 1.27 and a beta of 1.55. The company has a current ratio of 1.95, a quick ratio of 1.44 and a debt-to-equity ratio of 8.43.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $0.02 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is presently 10.39%.

Institutional Investors Weigh In On Organon & Co.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC grew its stake in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after buying an additional 2,033 shares in the last quarter. Allied Private Wealth LLC bought a new position in Organon & Co. during the second quarter valued at approximately $33,000. Eurizon Capital SGR S.p.A. bought a new position in Organon & Co. during the fourth quarter valued at approximately $44,000. Kestra Advisory Services LLC acquired a new stake in Organon & Co. in the fourth quarter valued at approximately $47,000. Finally, WNY Asset Management LLC acquired a new stake in Organon & Co. in the first quarter valued at approximately $64,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.